Patients with REM sleep behavior disorder have higher serum levels of allantoin
Language English Country Great Britain, England Media print-electronic
Document type Evaluation Study, Journal Article, Research Support, Non-U.S. Gov't
PubMed
34352609
DOI
10.1016/j.parkreldis.2021.07.031
PII: S1353-8020(21)00280-7
Knihovny.cz E-resources
- Keywords
- Allantoin, Oxidative stress, RBD, Synucleinopathy, Uric acid,
- MeSH
- Allantoin blood MeSH
- Biomarkers blood MeSH
- Tomography, Emission-Computed, Single-Photon MeSH
- Uric Acid blood MeSH
- Humans MeSH
- Oxidative Stress MeSH
- REM Sleep Behavior Disorder blood MeSH
- Aged MeSH
- Case-Control Studies MeSH
- Synucleinopathies blood MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Evaluation Study MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Allantoin MeSH
- Biomarkers MeSH
- Uric Acid MeSH
INTRODUCTION: Rapid eye movement (REM) sleep behavior disorder (RBD) is associated with an increased risk of developing Parkinson's disease (PD). Low uric acid (UA) levels are associated with the risk of development and progression of PD. Allantoin is the major oxidation product of UA and is considered as a biomarker of oxidative stress. We aimed to compare serum levels of UA, allantoin, and allantoin/UA ratio in RBD patients with those in healthy controls, and to examine their associations with clinical severity. METHODS: We evaluated serum levels of UA, allantoin, and allantoin/UA ratio in 38 RBD patients (one female, mean age 66.8 (SD 6.3) years) and in 47 controls (four females, 66.8 (7.6) years). All RBD patients were assessed according to an examination protocol, which included structured interview, Montreal Cognitive Assessment (MoCA), Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS), and dopamine transporter single-photon emission computed tomography (DAT-SPECT). The lower putaminal binding ratio from both hemispheres was used for analysis. RESULTS: Mean serum allantoin concentration and allantoin/UA ratio were significantly increased in the RBD group compared to controls (2.6 (1.8) vs. 1.4 (0.7) μmol/l, p = 0.0004, and 0.008 (0.004) vs. 0.004 (0.002), p < 0.0001, respectively). There were no significant differences in UA levels between the two groups. No significant associations between any biochemical parameter and RBD duration, putaminal binding ratio on DAT-SPECT, MDS-UPDRS, or MoCA score were found. CONCLUSION: Serum allantoin and allantoin/UA ratio are increased in RBD patients in comparison to controls, which may reflect increased systemic oxidative stress in prodromal synucleinopathy.
References provided by Crossref.org
Serum but not cerebrospinal fluid levels of allantoin are increased in de novo Parkinson's disease
